Tissue Regenix Group PLC First EU shipment & new distributor agreements
06 Février 2024 - 8:00AM
RNS Non-Regulatory
RNS Number : 0928C
Tissue Regenix Group PLC
06 February 2024
Tissue Regenix Group
plc
('Tissue Regenix',
the 'Company', or the 'Group')
First shipment and sale of allograft
products in the EU following HPRA approval
&
New distributor agreements signed for
Turkey and Ireland
Tissue Regenix (AIM: TRX), the
regenerative medical device company, announces that the first order
of its allograft products has been shipped from its third-party
Irish logistics hub, Biostór Ireland Ltd, following approval from
the Irish Health Products Regulatory Authority ('HPRA') in
October 2023.
The Irish logistics hub provides
a central European location for the distribution of Tissue
Regenix's allograft products throughout the European Union
('EU'), facilitating increased shipments across the EU
and aiding the potential for further partnerships
and distributor contracts within these countries.
Tissue Regenix also announces that
it has signed two new distributor agreements for its allograft
products in Turkey and Ireland (including Northern Ireland). These
agreements cover the dental and orthopaedic markets and continue
the expansion of the Company's EU coverage, following the recently
announced exclusive
distributor agreement in Spain with Spineart España SLU.
These developments are in line with the Group's commercial strategy of expanding its
distribution network and growing market share in other
jurisdictions outside the US in H2 2023.
Daniel Lee,
Chief Executive Officer of Tissue Regenix Group plc,
commented: "At our interims we outlined our intention
to more broadly distribute
allograft tissue products, and I am pleased to report the positive
progress we are making against this growth pillar. These new
distributor contracts, alongside the first shipment of products
from our Irish logistics hub, are a great step forward in the
Company's EU expansion plan into markets where we gain approvals
and demonstrate the effectiveness of our ongoing 4S strategy as we
scale the business outside of the US."
For more
information:
Tissue Regenix
Group plc
|
www.tissueregenix.com
|
David Cocke, Chief Financial Officer
|
via Walbrook
PR
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
|
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
|
|
Nigel Birks/Harriet Ward - ECM
|
|
|
|
Walbrook PR (Financial PR and IR)
|
Tel: +44
(0)20 7933 8780
|
Charlotte Edgar / Alice Woodings
|
TissueRegenix@walbrookpr.com
|
|
|
About Tissue Regenix
(www.tissueregenix.com)
Tissue Regenix is a leading medical device
company in regenerative medicine. The Company's patented
decellularisation technology (dCELL®) removes DNA and other
cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that
can be used to repair diseased or damaged body structures. Current
applications address many crucial clinical needs in sports
medicine, foot and ankle injuries and wound care.
This information is provided by Reach, the non-regulatory
press release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NRADGGDDUGGDGSU
Tissue Regenix (LSE:TRX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Tissue Regenix (LSE:TRX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024